Medicines and Healthcare Products Regulatory Agency

An executive agency, also called MHRA

944 requests
Make a Freedom of Information request to this authority
Safety signal and related safety event reporting for UK CV19 vaccine products
Response by Medicines and Healthcare Products Regulatory Agency to Mr B Kingsley on .

Partially successful.

FOI 23/162 Dear Mr B Kingsley, Thank you for your email and we apologise for delay in response. Please find attached the response to your FOI reques...
Recent evidence on vape regulatory enforcement in the UK
Response by Medicines and Healthcare Products Regulatory Agency to Jordan Millar on .

Delayed.

Dear Jordan Millar, Thank you for your email. We acknowledge that the request is outstanding and we apologise for the delay. Kind Regards MHRA Cust...
Replacement for Adcortyl in Orabase
Response by Medicines and Healthcare Products Regulatory Agency to Michelle vonAhn on .

Partially successful.

Dear Michelle vonAhn,   Thank you for your enquiry relating to Adcortyl in orabase, please see our comments below: Adcortyl in orabase for mouth...
Data for effectiveness of Covid-19 Innova rapid test used in health-/care settings
Internal review request sent to Medicines and Healthcare Products Regulatory Agency by Mia Cartwright on .

Awaiting internal review.

Dear MHRA Customer Services, Re FOI 22/1219 Thank you for your reply to my request. Thank you also for clarifying the status of the Innova 25 devi...
Fluenz Tetra nasal spray suspension Influenza vaccine (live attenuated, nasal)
Response by Medicines and Healthcare Products Regulatory Agency to Malcolm Day on .

Awaiting classification.

FOI 23/326 Dear Malcolm Day, Thank you for your email of 1st May where you have asked "please provide the following information for the Fluenz Tetra...
Rybelsus Parallel Import (PLPI) Licences
Response by Medicines and Healthcare Products Regulatory Agency to Tom Henderson Silva on .

Successful.

Dear Tom, Thank you for your enquiry to the MHRA. There are no UK parallel import licences (PLPIs) that have been granted for Rybelsus according to o...
ICH guideline S1B(R1) on testing for carcinogenicity of pharmaceuticals
Response by Medicines and Healthcare Products Regulatory Agency to Alice Sav on .

Awaiting response.

Our Ref: FOI 23/383 Dear Alice Sav, RE: REQUEST UNDER THE FREEDOM OF INFORMATION ACT 2000 Thank you for your enquiry which we received on 25th May....
Updated Yellow card data for the Isle of Man on Covid-19 vaccines
Response by Medicines and Healthcare Products Regulatory Agency to Natalie Birchall on .

Awaiting classification.

Our Ref: FOI 23/381 Dear Natalie Birchall RE: REQUEST UNDER THE FREEDOM OF INFORMATION ACT 2000 Thank you for your enquiry which we will commence re...
MHRA Internal communications relating to FOIA Request 23/105
Request to Medicines and Healthcare Products Regulatory Agency by CHP Gillow. Annotated by CHP Gillow on .

Delayed.

Complaint submitted to ICO
Internal Communication in respect of FOIA request 23/073
Request to Medicines and Healthcare Products Regulatory Agency by CHP Gillow. Annotated by CHP Gillow on .

Delayed.

Complaint submitted to ICO
Lipid-related impurity issues for BNT162b2
Follow up sent to Medicines and Healthcare Products Regulatory Agency by Jonathan Weissman on .

Awaiting response.

Dear MHRA Customer Services, Given the ICO's decision notice dated 6 March 2023 [1] compels the MHRA to respond to all 5 of my FOI requests previousl...
Section 3.2.P.1 for all approved COVID-19 vaccines
Follow up sent to Medicines and Healthcare Products Regulatory Agency by Jonathan Weissman on .

Long overdue.

Dear MHRA Customer Services, Over two months have now passed since I raised this request. Your response to this request is long overdue. Please provi...
Contamination, exact ingredients and WFI GMP for Pfizer's product BNT162b2
Response by Medicines and Healthcare Products Regulatory Agency to Jonathan Weissman on .

Partially successful.

Internal Review of FOI 22/387   Dear Mr Jonathan Weissman   Thank you for your email.   Please find attached the reply to your Internal Rev...
Important protocol deviations within 7 days after Dose 2 in BNT162b2 clinical trial
Response by Medicines and Healthcare Products Regulatory Agency to Jonathan Weissman on .

Partially successful.

FOI 23/211   Dear Mr Weissman,   Thank you for your information request dated 19 February 2022 where you asked for information related COVID-1...
NaOH and HCl Excipients in Pfizer’s SmPC for Comirnaty
Response by Medicines and Healthcare Products Regulatory Agency to Jonathan Weissman on .

Partially successful.

FOI 23/325   Dear Mr Weissman,   Thank you for your request under the Freedom of Information Act, we apologise for the delay in response.  ...
Wholesale Inpection Defficiencies
Response by Medicines and Healthcare Products Regulatory Agency to Michael Devlin on .

Awaiting classification.

Mr Devlin Apologies for the delay. Reg 43 (5) of the 2012 Human Medicines Regulations provides a WDA holder mut not sell supply or offer a medicine un...
Pfizer BNT162b2 conditions of authorisation
Response by Medicines and Healthcare Products Regulatory Agency to Alex Hicks on .

Awaiting classification.

Our ref: FOI: 23/150 Dear Alex Hicks, Thank you for your request under the Freedom of Information Act, we apologise for the delay in response. We ha...
FOIA request - MHRA Managing Medical Devices - Guidance for health and social care organisations - January 2021
Response by Medicines and Healthcare Products Regulatory Agency to Marc Jordan on .

Long overdue.

Internal Review of FOI 23/218 Dear Marc Jordan, Thank you for your email. We confirm that an internal review will be carried out on FOI 23/218. We n...
Disclosure Log - List of FOIA requests answered fully or in part since 1 January 2021 including requests where the MHRA holds no information
Follow up sent to Medicines and Healthcare Products Regulatory Agency by CHP Gillow on .

Awaiting classification.

Dear MHRA Customer Services, To clarify the position: This request was submitted on 18 January 2023. I was asking you to make available the disc...
Inventory of items submitted in support of Vaxzevria's Temporary and Conditional Marketing Authorisations
Response by Medicines and Healthcare Products Regulatory Agency to CHP Gillow on .

Awaiting classification.

Our ref: FOI 23/073   Dear Mr Gillow,   Thank you for your request of 27 January 2023, we apologise for the long delay in reply.   We have...
Nucleotide base sequence for "davesomeran"
Response by Medicines and Healthcare Products Regulatory Agency to Matt Cooper on .

Awaiting classification.

Dear Mr Cooper,   Please find attached, the final response to the above-referenced Freedom of Information request.         Kind regards,  ...
COVID-19 vaccine data
Response by Medicines and Healthcare Products Regulatory Agency to DAVID on .

Awaiting response.

Our Ref: FOI 23/358 Dear Mr D Tait, RE: REQUEST UNDER THE FREEDOM OF INFORMATION ACT 2000 Thank you for your enquiry which we received on 19th May....
Specification for dsDNA concentration in mRNA COVID-19 vaccine products
Response by Medicines and Healthcare Products Regulatory Agency to Matt Cooper on .

Awaiting classification.

FOI 23/236   Dear Matt Cooper,   Thank you for your email of 29th March where you have asked " Please release the specification and/or tolerance f...
IBI Corr
Response by Medicines and Healthcare Products Regulatory Agency to JJ Evans on .

Long overdue.

Our Ref: FOI 23/181 Dear JJ Evans, RE: REQUEST UNDER THE FREEDOM OF INFORMATION ACT 2000 Thank you for your enquiry which we received on 10 March 20...
Requesting Data from any completed Clinical Trial for my MSc Data Science Dissertation project and research
Response by Medicines and Healthcare Products Regulatory Agency to Ankurkumar Maganbhai Sangani on .

Refused.

FOI 23/209 Dear Ankur Sangani, Thank you for your email. We do not receive these so we cannot provide the data and we advise that you contact the tr...

Only requests made using WhatDoTheyKnow are shown. ?